Have a read.
From an old article.
IMU’s front runner drug candidate HER-Vaxx, is already in Phase 1b and Phase 2 trials and is interestingly further advanced than Regeneron’s cancer therapies before Regeneron was acquired for $1.6 billion by Roche.
IMU is looking to attract big pharma’s attention by 2020.
HER-Vaxx targets the same receptor as the two leading antibody drugs on the market, Herceptin and Perjeta, with annual sales of US$8.2 billion in a market predicted to generate sales of US$36 billion by 2025.
IMU is looking to commercialise a treatment that has improved efficacy over existing treatments and is more cost efficient, which would give it a strong position in this market.
https://www.nextbiotech.com.au/company/imu/
Cheers
Have a read. From an old article. IMU’s front runner drug...
-
- There are more pages in this discussion • 1,561 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
-0.001(2.13%) |
Mkt cap ! $353.3M | |||
| Open | High | Low | Value | Volume |
| 4.7¢ | 4.8¢ | 4.5¢ | $376.2K | 8.082M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 1004677 | 4.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.7¢ | 1040062 | 13 |
View Market Depth
| Last trade - 11.15am 06/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |